|
US2012328687A1
|
|
Formulations of selective alpha-2 agonists and methods of use thereof
|
|
US2012309804A1
|
|
Compositions and methods for treatment of glaucoma
|
|
US2012309720A1
|
|
Compositions and methods for treatment of glaucoma
|
|
US2012156244A1
|
|
Nasal Compositions and Uses Thereof
|
|
US2012202864A1
|
|
Compositions and Methods for Treatment of Glaucoma
|
|
US2011257188A1
|
|
Compositions and methods for the treatment of nasal conditions
|
|
US2011244058A1
|
|
Compositions and methods for treatment of pulmonary diseases and conditions
|
|
US2012202863A1
|
|
Compositions and methods for treatment of glaucoma
|
|
US2011152271A1
|
|
Compositions and methods for ophthalmic delivery of nasal decongestants
|
|
US2010203165A1
|
|
Compositions and methods for treatment of disorders or conditions of the eye
|
|
US2010197694A1
|
|
Compositions and methods for treatment of diseases and conditions with increased vascular permeability
|
|
US2010202979A1
|
|
Compositions and methods for treatment of pulmonary diseases and conditions
|
|
US2010029663A1
|
|
Compositions and methods for reducing activation of alpha-1 receptors
|
|
WO2006055707A2
|
|
Composition and method for modifying contact lens shape
|
|
US8889112B2
|
|
Ophthalmic formulations including selective alpha 1 antagonists
|
|
CA2428233A1
|
|
A method and apparatus for the correction of presbyopia using high intensity focused ultrasound
|
|
US5061059A
|
|
Self-detection glaucoma test method
|
|
US4888012A
|
|
Intraocular lens assemblies
|
|
US4619256A
|
|
Intraocular lens inserting assembly
|
